Finch A,Kubler P. .2016 .The management of gout. Aust Prescr, 10(4) : 119-22.
Graf SW,Whittle SL,Wechalekar MD,Moi JH,Barrett C,Hill CL .2015 .Australian and New Zealand recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion in the 3e Initiative. Int J Rheum Dis, 10(3) : 12557-185x.
Robinson PC,Horsburgh S.,Gout S. .2014 .: joints and beyond, epidemiology, clinical features, treatment and co-morbidities. Maturitas, 05(4) : 245-51.
Zhu Y,Pandya BJ,Choi HK .2011 .Comorbidities of gout and hyperuricemia in the US general population: NHANES 2007-2008. Am J Med, 09(7) : 679-87.
Robinson PC,Taylor WJ,Merriman TR .2012 .Systematic review of the prevalence of gout and hyperuricaemia in Australia. Int Med, 02794(9) : 5994-1007.
Smith EU,Diaz-Torne C,Perez-Ruiz F,March LM .2010 .Epidemiology of gout: an update. Best Pract Res Clin Rheumatol, 10(6) : 811-27.
Alghamdi AA,Mutlaqah MA,Amal Mohammed H,Labani LM,Alahmari AF,Abdulrahman R .2021 .Gout management in primary care approach; Literature Review. Int J Pharm Res Allied Sci, 10(1) : 19-23.
Bove M,Cicero AF,Veronesi M,Borghi C. .2017 .An evidence-based review on urate-lowering treatments: implications for optimal treatment of chronic hyperuricemia. Vasc Health Risk Manag, 10 : 23-8.
Viggiano D,Gigliotti G,Vallone G,Giammarino A,Nigro M,Capasso G .2018 .Urate-lowering agents in asymptomatic hyperuricemia: role of urine sediment analysis and musculoskeletal ultrasound. Kidney Blood Press Res, 10(2) : 606-15.
Watanabe S,Kang DH,Feng L,Nakagawa T,Kanellis J,Lan H .2002 .Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension, 0000028589(3) : 355-60.
Viggiano A,Viggiano D,Viggiano A,Luca BD .2003 .Quantitative histochemical assay for superoxide dismutase in rat brain. J Histochem Cytochem, 10(7) : 865-71.
Perna AF,Di Nunzio A,Amoresano A,Pane F,Fontanarosa C,Pucci P .2016 .Divergent behavior of hydrogen sulfide pools and of the sulfur metabolite lanthionine, a novel uremic toxin, in dialysis patients. Biochimie, 04 : 97-107.
Ragab G,Elshahaly M,Bardin T.,Gout T. .2017 .An old disease in new perspective-A review. J Adv Res, 04(5) : 495-511.
Dalbeth N,Merriman TR,Stamp LK .2016 .. , 6736(16) : 00346-9.
Mandal AK,Mount DB .2015 .The molecular physiology of uric acid homeostasis. Annu Rev Physiol, 021113(1) : 323-45.
Kamei K,Konta T,Hirayama A,Suzuki K,Ichikawa K,Fujimoto S .2014 .A slight increase within the normal range of serum uric acid and the decline in renal function: associations in a community-based population. Nephrol Dial Transplant, 10(12) : 2286-92.
Torres RJ,Puig JG .2007 .Hypoxanthine-guanine phosophoribosyltransferase (HPRT) deficiency: Lesch-Nyhan syndrome. Orphanet J Rare Dis, 10(1) : 1750-0.
Kanbara A,Seyama I .2011 .Effect of urine pH on uric acid excretion by manipulating food materials. Nucleosides Nucleotides Nucleic Acids, 10(12) : 1066-71.
Dessein PH,Shipton EA,Stanwix AE,Joffe BI,Ramokgadi J .2000 .Beneficial effects of weight loss associated with moderate calorie/carbohydrate restriction, and increased proportional intake of protein and unsaturated fat on serum urate and lipoprotein levels in gout: a pilot study. Ann Rheum Dis, 10(7) : 539-43.
Ichida K,Matsuo H,Takada T,Nakayama A,Murakami K,Shimizu T .2012 .Decreased extra-renal urate excretion is a common cause of hyperuricemia. Nat Commun, 10(1) : 1-7.
Bobulescu IA,Moe OW .2012 .Renal transport of uric acid: evolving concepts and uncertainties. Adv Chronic Kidney Dis, 07(6) : 358-71.
Han J,Liu Y,Rao F,Nievergelt CM,O'Connor DT,Wang X .2012 .Common genetic variants of the human uromodulin gene regulate transcription and predict plasma uric acid levels. Kidney Int, 10(4) : 733-40.
Perez-Ruiz F,Dalbeth N,Bardin T. .2015 .A review of uric acid, crystal deposition disease, and gout. Adv Ther, 10(1) : 31-41.
Robinson PC,Dalbeth N. .2015 .Advances in pharmacotherapy for the treatment of gout. Expert Opin Pharmacother, 10(4) : 533-46.
Strilchuk L,Fogacci F,Cicero AF .2019 .Safety and tolerability of available urate-lowering drugs: a critical review. Expert Opin Drug Saf, 10(4) : 261-71.
Pittman JR,Bross MH .1999 .Diagnosis and management of gout. Am Fam Physician, 59(7) : 1799-806.
Khanna D,Fitzgerald JD,Khanna PP,Bae S,Singh MK,Neogi T .2012 .American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res, 10(10) : 1431-46.
Rees F,Hui M,Doherty M. .2014 .Optimizing current treatment of gout. Nat Rev Rheumatol, 10(5) : 271-83.
Sundy JS,Ganson NJ,Kelly SJ,Scarlett EL,Rehrig CD,Huang W .2007 .Pharmacokinetics and pharmacodynamics of intravenous PEGylated recombinant mammalian urate oxidase in patients with refractory gout. Arthritis Rheum, 10(3) : 1021-8.
Day RO,Graham GG,Hicks M,McLachlan AJ,Stocker SL,Williams KM. .2007 .Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet, 10(8) : 00003088-44.
Stamp LK,Taylor WJ,Jones PB,Dockerty JL,Drake J,Frampton C .2012 .Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis Rheum, 10(8) : 2529-36.
Ghislain PD,Roujeau JC .2002 .Treatment of severe drug reactions: StevensJohnson syndrome, toxic epidermal necrolysis and hypersensitivity syndrome. Dermatol Online J, 10(1) : .
Stamp LK,Barclay ML .2018 .How to prevent allopurinol hypersensitivity reactions?. Rheumatology, 10(suppl) : i35-41.
Ramasamy SN,Korb-Wells CS,Kannangara DR,Smith MW,Wang N,Roberts DM .2013 .Allopurinol hypersensitivity: a systematic review of all published cases,. , 10(10) : 953-80.
Benn CL,Dua P,Gurrell R,Loudon P,Pike A,Storer RI .2018 .Physiology of hyperuricemia and urate-lowering treatments. Front Med, 10 : 160.
Caulfield MJ,Munroe PB,O'Neill D,Witkowska K,Charchar FJ,Doblado M .2008 .SLC2A9 is a high-capacity urate transporter in humans. PLoS Med, 10(10) : .
Huang CH,Chu MP,Chen WW .2018 .Examining the use of allopurinol: perspectives from recent drug injury relief applications. J Formos Med Assoc, 06(1) : 371-7.
Pascual E,Sivera F,Yasothan U,Kirkpatrick P.,Febuxostat P. .2009 .. Nat Rev Drug Discov, 10(3) : 191-3.
Borghi C,Cicero AF .2017 .. Serum Uric Acid and Cardiometabolic Disease. Hypertension, 10(6) : 1011-3.
Schumacher Jr HR,Becker MA,Wortmann RL,MacDonald PA,Hunt B,Streit J .2008 .Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28‐ week, phase III, randomized, double‐blind, parallel‐group trial. Arthritis Care Res, 10(11) : 1540-8.
White WB,Saag KG,Becker MA,Borer JS,Gorelick PB,Whelton A .2018 .Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Eng J Med, 10(13) : 1200-10.
Katsiki N,Borghi C. .2018 .The future of febuxostat after the Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Gout and Cardiovascular Morbidities (CARES) trial: who CARES?. Expert Opin Pharmacother, 10(17) : 1853-6.
Jordan A,Gresser U .2018 .Side effects and interactions of the xanthine oxidase inhibitor febuxostat. Pharmaceuticals, 10(2) : 51.
Hosoya T,Ogawa Y,Hashimoto H,Ohashi T,Sakamoto R .2016 .Comparison of topiroxostat and allopurinol in Japanese hyperuricemic patients with or without gout: A phase 3, multicentre, randomized, double‐blind, double‐dummy, active‐controlled, parallel‐group study. J Clin Pharm Ther, 10(3) : 290-7.
Horino T,Hatakeyama Y,Ichii O,Matsumoto T,Shimamura Y,Inoue K .2018 .Effects of topiroxostat in hyperuricemic patients with chronic kidney disease. Clin Exp Nephrol, 10(2) : 337-45.
Sato T,Ashizawa N,Matsumoto K,Iwanaga T,Nakamura H,Inoue T .2009 .-a xanthine oxidoreductase inhibitor for the treatment of hyperuricemia. Bioorg Med Chem Lett, 08(21) : 6225-9.
Hosoya T,Sasaki T,Ohashi T. .2017 .Clinical efficacy and safety of topiroxostat in Japanese hyperuricemic patients with or without gout: a randomized, double-blinded, controlled phase 2b study. Clin Rheumtol, 10(3) : 649-56.
Greig D,Alcaino H,Castro PF,Garcia L,Verdejo HE,Navarro M .2010 .Xanthine-oxidase inhibitors and statins in chronic heart failure: effects on vascular and functional parameters. J Heart Lung Transplant, 10(4) : 408-13.
Mizukoshi T,Kato S,Ando M,Sobajima H,Ohashi N,Naruse T .2018 .Renoprotective effects of topiroxostat for hyperuricaemic patients with overt diabetic nephropathy study (ETUDE study): a prospective, randomized, multicentre clinical trial. Nephrology, 10(11) : 1023-30.
Sezai A,Obata K,Abe K,Kanno S,Sekino H .2017 .Cross-over trial of febuxostat and topiroxostat for hyperuricemia with cardiovascular disease (TROFEO trial). Circ J, 17(11) : 1707-12.